Compile Data Set for Download or QSAR
Report error Found 216 Enz. Inhib. hit(s) with all data for entry = 10711
TargetMonoglyceride lipase(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM561384(US11390610, Example 213)
Affinity DataIC50: 3nMAssay Description:Compounds of the present invention are MAGL inhibitors. Thus, in one aspect, the present invention provides the use of compounds of Formula (I) or a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM561025(US11390610, Example 67)
Affinity DataIC50: 4.40nMAssay Description:Compounds of the present invention are MAGL inhibitors. Thus, in one aspect, the present invention provides the use of compounds of Formula (I) or a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM561217(US11390610, Example 116)
Affinity DataIC50: 5nMAssay Description:Compounds of the present invention are MAGL inhibitors. Thus, in one aspect, the present invention provides the use of compounds of Formula (I) or a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM561355(US11390610, Example 184)
Affinity DataIC50: 5nMAssay Description:Compounds of the present invention are MAGL inhibitors. Thus, in one aspect, the present invention provides the use of compounds of Formula (I) or a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM561381(US11390610, Example 210)
Affinity DataIC50: 6nMAssay Description:Compounds of the present invention are MAGL inhibitors. Thus, in one aspect, the present invention provides the use of compounds of Formula (I) or a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM561341(US11390610, Example 170)
Affinity DataIC50: 7nMAssay Description:Compounds of the present invention are MAGL inhibitors. Thus, in one aspect, the present invention provides the use of compounds of Formula (I) or a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM561367(US11390610, Example 196)
Affinity DataIC50: 7nMAssay Description:Compounds of the present invention are MAGL inhibitors. Thus, in one aspect, the present invention provides the use of compounds of Formula (I) or a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM561328(US11390610, Example 157)
Affinity DataIC50: 10nMAssay Description:Compounds of the present invention are MAGL inhibitors. Thus, in one aspect, the present invention provides the use of compounds of Formula (I) or a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM561382(US11390610, Example 211)
Affinity DataIC50: 11nMAssay Description:Compounds of the present invention are MAGL inhibitors. Thus, in one aspect, the present invention provides the use of compounds of Formula (I) or a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM561368(US11390610, Example 197)
Affinity DataIC50: 12nMAssay Description:Compounds of the present invention are MAGL inhibitors. Thus, in one aspect, the present invention provides the use of compounds of Formula (I) or a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM561363(US11390610, Example 192)
Affinity DataIC50: 14nMAssay Description:Compounds of the present invention are MAGL inhibitors. Thus, in one aspect, the present invention provides the use of compounds of Formula (I) or a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM561375(US11390610, Example 204)
Affinity DataIC50: 16nMAssay Description:Compounds of the present invention are MAGL inhibitors. Thus, in one aspect, the present invention provides the use of compounds of Formula (I) or a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM561019(US11390610, Example 61)
Affinity DataIC50: 19nMAssay Description:Compounds of the present invention are MAGL inhibitors. Thus, in one aspect, the present invention provides the use of compounds of Formula (I) or a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM561038(US11390610, Example 75)
Affinity DataIC50: 19nMAssay Description:Compounds of the present invention are MAGL inhibitors. Thus, in one aspect, the present invention provides the use of compounds of Formula (I) or a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM560942(US11390610, Example 1 | US11390610, Example 160)
Affinity DataIC50: 20nMAssay Description:Compounds of the present invention are MAGL inhibitors. Thus, in one aspect, the present invention provides the use of compounds of Formula (I) or a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM561034(US11390610, Example 73)
Affinity DataIC50: 20nMAssay Description:Compounds of the present invention are MAGL inhibitors. Thus, in one aspect, the present invention provides the use of compounds of Formula (I) or a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM561046(US11390610, Example 83)
Affinity DataIC50: 20nMAssay Description:Compounds of the present invention are MAGL inhibitors. Thus, in one aspect, the present invention provides the use of compounds of Formula (I) or a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM561299(US11390610, Example 128)
Affinity DataIC50: 20nMAssay Description:Compounds of the present invention are MAGL inhibitors. Thus, in one aspect, the present invention provides the use of compounds of Formula (I) or a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM561068(US11390610, Example 96)
Affinity DataIC50: 22nMAssay Description:Compounds of the present invention are MAGL inhibitors. Thus, in one aspect, the present invention provides the use of compounds of Formula (I) or a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM561373(US11390610, Example 202)
Affinity DataIC50: 22nMAssay Description:Compounds of the present invention are MAGL inhibitors. Thus, in one aspect, the present invention provides the use of compounds of Formula (I) or a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM561362(US11390610, Example 191)
Affinity DataIC50: 23nMAssay Description:Compounds of the present invention are MAGL inhibitors. Thus, in one aspect, the present invention provides the use of compounds of Formula (I) or a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM561020(US11390610, Example 62)
Affinity DataIC50: 24nMAssay Description:Compounds of the present invention are MAGL inhibitors. Thus, in one aspect, the present invention provides the use of compounds of Formula (I) or a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM561364(US11390610, Example 193)
Affinity DataIC50: 25nMAssay Description:Compounds of the present invention are MAGL inhibitors. Thus, in one aspect, the present invention provides the use of compounds of Formula (I) or a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM561099(US11390610, Example 112)
Affinity DataIC50: 27nMAssay Description:Compounds of the present invention are MAGL inhibitors. Thus, in one aspect, the present invention provides the use of compounds of Formula (I) or a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM561024(US11390610, Example 66)
Affinity DataIC50: 30nMAssay Description:Compounds of the present invention are MAGL inhibitors. Thus, in one aspect, the present invention provides the use of compounds of Formula (I) or a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM561033(US11390610, Example 72)
Affinity DataIC50: 32nMAssay Description:Compounds of the present invention are MAGL inhibitors. Thus, in one aspect, the present invention provides the use of compounds of Formula (I) or a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM561327(US11390610, Example 156)
Affinity DataIC50: 32nMAssay Description:Compounds of the present invention are MAGL inhibitors. Thus, in one aspect, the present invention provides the use of compounds of Formula (I) or a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM561039(US11390610, Example 76)
Affinity DataIC50: 33nMAssay Description:Compounds of the present invention are MAGL inhibitors. Thus, in one aspect, the present invention provides the use of compounds of Formula (I) or a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM561366(US11390610, Example 195 | 2-[4-[3-(3-Chlorophenyl)...)
Affinity DataIC50: 34nMAssay Description:Compounds of the present invention are MAGL inhibitors. Thus, in one aspect, the present invention provides the use of compounds of Formula (I) or a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM560969(US11390610, Example 17)
Affinity DataIC50: 36nMAssay Description:Compounds of the present invention are MAGL inhibitors. Thus, in one aspect, the present invention provides the use of compounds of Formula (I) or a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM561302(US11390610, Example 131)
Affinity DataIC50: 36nMAssay Description:Compounds of the present invention are MAGL inhibitors. Thus, in one aspect, the present invention provides the use of compounds of Formula (I) or a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM560956(US11390610, Example 12)
Affinity DataIC50: 37nMAssay Description:Compounds of the present invention are MAGL inhibitors. Thus, in one aspect, the present invention provides the use of compounds of Formula (I) or a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM561329(US11390610, Example 158)
Affinity DataIC50: 39nMAssay Description:Compounds of the present invention are MAGL inhibitors. Thus, in one aspect, the present invention provides the use of compounds of Formula (I) or a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM561088(US11390610, Example 104)
Affinity DataIC50: 41nMAssay Description:Compounds of the present invention are MAGL inhibitors. Thus, in one aspect, the present invention provides the use of compounds of Formula (I) or a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM561090(US11390610, Example 106)
Affinity DataIC50: 41nMAssay Description:Compounds of the present invention are MAGL inhibitors. Thus, in one aspect, the present invention provides the use of compounds of Formula (I) or a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM561029(US11390610, Example 69)
Affinity DataIC50: 42nMAssay Description:Compounds of the present invention are MAGL inhibitors. Thus, in one aspect, the present invention provides the use of compounds of Formula (I) or a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM561218(US11390610, Example 117)
Affinity DataIC50: 42nMAssay Description:Compounds of the present invention are MAGL inhibitors. Thus, in one aspect, the present invention provides the use of compounds of Formula (I) or a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM561321(US11390610, Example 150)
Affinity DataIC50: 42nMAssay Description:Compounds of the present invention are MAGL inhibitors. Thus, in one aspect, the present invention provides the use of compounds of Formula (I) or a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM561011(US11390610, Example 54)
Affinity DataIC50: 44nMAssay Description:Compounds of the present invention are MAGL inhibitors. Thus, in one aspect, the present invention provides the use of compounds of Formula (I) or a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM561345(US11390610, Example 174)
Affinity DataIC50: 45nMAssay Description:Compounds of the present invention are MAGL inhibitors. Thus, in one aspect, the present invention provides the use of compounds of Formula (I) or a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM561229(US11390610, Example 119)
Affinity DataIC50: 46nMAssay Description:Compounds of the present invention are MAGL inhibitors. Thus, in one aspect, the present invention provides the use of compounds of Formula (I) or a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM561346(US11390610, Example 175 | 2-[4-[3-Chloro-4-[(4-chl...)
Affinity DataIC50: 48nMAssay Description:Compounds of the present invention are MAGL inhibitors. Thus, in one aspect, the present invention provides the use of compounds of Formula (I) or a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM560954(US11390610, Example 10)
Affinity DataIC50: 49nMAssay Description:Compounds of the present invention are MAGL inhibitors. Thus, in one aspect, the present invention provides the use of compounds of Formula (I) or a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM561306(US11390610, Example 135)
Affinity DataIC50: 49nMAssay Description:Compounds of the present invention are MAGL inhibitors. Thus, in one aspect, the present invention provides the use of compounds of Formula (I) or a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM560942(US11390610, Example 1 | US11390610, Example 160)
Affinity DataIC50: 49nMAssay Description:Compounds of the present invention are MAGL inhibitors. Thus, in one aspect, the present invention provides the use of compounds of Formula (I) or a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM560943(US11390610, Example 2)
Affinity DataIC50: 50nMAssay Description:Compounds of the present invention are MAGL inhibitors. Thus, in one aspect, the present invention provides the use of compounds of Formula (I) or a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM561298(US11390610, Example 127)
Affinity DataIC50: 50nMAssay Description:Compounds of the present invention are MAGL inhibitors. Thus, in one aspect, the present invention provides the use of compounds of Formula (I) or a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM561005(US11390610, Example 48)
Affinity DataIC50: 51nMAssay Description:Compounds of the present invention are MAGL inhibitors. Thus, in one aspect, the present invention provides the use of compounds of Formula (I) or a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM561340(US11390610, Example 169)
Affinity DataIC50: 52nMAssay Description:Compounds of the present invention are MAGL inhibitors. Thus, in one aspect, the present invention provides the use of compounds of Formula (I) or a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
Go to US Patent

TargetMonoglyceride lipase(Human)
Hoffmann-La Roche

US Patent
LigandPNGBDBM561356(US11390610, Example 185)
Affinity DataIC50: 52nMAssay Description:Compounds of the present invention are MAGL inhibitors. Thus, in one aspect, the present invention provides the use of compounds of Formula (I) or a ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2022
Entry Details
Go to US Patent

Displayed 1 to 50 (of 216 total ) | Next | Last >>
Jump to: